These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29088323)

  • 1. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.
    Armstrong AJ; Antonarakis ES; Taplin ME; Kelly WK; Beltran H; Fizazi K; Dahut WL; Shore N; Slovin S; George D; Carducci MA; Corn P; Danila D; Dreicer R; Heath E; Rathkopf D; Liu G; Nanus D; Stein M; Smith MR; Sternberg C; Wilding G; Nelson PS; Halabi S; Kantoff P; Clarke NW; Evans CP; Heidenreich A; Mottet N; Gleave M; Morris MJ; Scher HI
    Ann Oncol; 2018 Jan; 29(1):23-25. PubMed ID: 29088323
    [No Abstract]   [Full Text] [Related]  

  • 2. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.
    Pezaro CJ; Omlin A; Mastris K; ; Attard G; Beer TM; Chi KN; Chowdhury S; Davis ID; Drake CG; de Bono JS; Efstathiou E; Gravis G; Higano CS; Hussain M; James N; Logothetis CJ; Morgans A; Parker C; Ryan CJ; Saad F; Sartor O; Small EJ; Sternberg CN; Sweeney CJ; Tannock I; Tombal B; Gillessen S
    Ann Oncol; 2017 Aug; 28(8):1692-1694. PubMed ID: 28838209
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating metastatic prostate cancer now and in the future.
    Meng MV; Boughey JC
    Bull Am Coll Surg; 2014 Sep; 99(9):55-7. PubMed ID: 25272429
    [No Abstract]   [Full Text] [Related]  

  • 4. Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
    Tsao CK; Galsky MD; Oh WK
    Eur Urol; 2014 Aug; 66(2):184-5. PubMed ID: 24433812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Castration-naive metastatic prostate cancer: reshaping old paradigms.
    Ratta R; Grassi P; Fucà G; Verzoni E; Procopio G
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):879-881. PubMed ID: 28854837
    [No Abstract]   [Full Text] [Related]  

  • 6. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
    Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
    Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approaches to immunotherapy for metastatic castration-resistant prostate cancer.
    Subudhi SK
    Clin Adv Hematol Oncol; 2019 May; 17(5):283-286. PubMed ID: 31188806
    [No Abstract]   [Full Text] [Related]  

  • 9. Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer-The Forgotten Dance Partner?
    Klaassen Z; Wallis CJD; Fleshner NE
    JAMA Oncol; 2019 Feb; 5(2):144-145. PubMed ID: 30489621
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
    Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.
    Heidenreich A; Pfister D; Merseburger A; Bartsch G;
    Eur Urol; 2013 Aug; 64(2):260-5. PubMed ID: 23706522
    [No Abstract]   [Full Text] [Related]  

  • 12. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.
    Karzai FH; Madan RA; Figg WD
    South Med J; 2015 Apr; 108(4):224-8. PubMed ID: 25871992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Docetaxel and prostate cancer: Early but not too early].
    Penel N; Ryckewaert T; Amela EY
    Bull Cancer; 2015 Sep; 102(9):710-2. PubMed ID: 26235414
    [No Abstract]   [Full Text] [Related]  

  • 14. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 15. One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?
    Loriot Y; Massard C; Fizazi K
    Eur Urol; 2014 Oct; 66(4):653-4. PubMed ID: 24735730
    [No Abstract]   [Full Text] [Related]  

  • 16. Updates on radium-223 for castration-resistant prostate cancer presented at the Genitourinary Cancers Symposium, January 7-9, 2016, San Francisco, California.
    Barkin J
    Can J Urol; 2016 Jun; 23(3):8306-7. PubMed ID: 27347626
    [No Abstract]   [Full Text] [Related]  

  • 17. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Griebling TL
    J Urol; 2015 Feb; 193(2):541. PubMed ID: 25617274
    [No Abstract]   [Full Text] [Related]  

  • 19. Galeterone activity in castration-resistant prostate cancer.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
    Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.